🇺🇸 FDA
Pipeline program

HMB-002 (Part A)

HMB-002-102

Phase 2 small_molecule active

Quick answer

HMB-002 (Part A) for Von Willebrand Disease (VWD) is a Phase 2 program (small_molecule) at Hemab Therapeutics Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Hemab Therapeutics Holdings
Indication
Von Willebrand Disease (VWD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials